title: Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA.
abstract: Staphylococcus aureus bacteremia (SAB) is an urgent medical problem due to its growing frequency and its poor associated outcome. As healthcare delivery increasingly involves invasive procedures and implantable devices, the number of patients at risk for SAB and its complications is likely to grow. Compounding this problem is the growing prevalence of methicillin-resistant S. aureus (MRSA) and the dwindling efficacy of vancomycin, long the treatment of choice for this pathogen. Despite the recent availability of several new antibiotics for S. aureus, new strategies for treatment and prevention are required for this serious, common cause of human infection.
authors.affiliation: Department of Cardiology, Copenhagen University Hospital, Gentofte, Copenhagen, Denmark.
authors.forename: Rasmus V
authors.initials: RV
authors.lastname: Rasmussen
authors.forename: Vance G
authors.initials: VG
authors.lastname: Fowler
authors.forename: Robert
authors.initials: R
authors.lastname: Skov
authors.forename: Niels E
authors.initials: NE
authors.lastname: Bruun
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology; D004696:Endocarditis / Q000382:microbiology; D006801:Humans; D058751:Livestock / Q000382:microbiology; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin